ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2020 Revenues and Provides 2021 Strategic Outlook

NEXT STORY
TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China for Priority Review
PREV STORY
PharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine Formulation Targeting Mental Health, Neurological and Pain Disorders
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Vital Therapies Appoints Former Receptos President and CEO Faheem Hasnain as Chairman of the Board of Directors

SAN DIEGO, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic ...

author_avatar
NASDAQ Market News

Immunicum AB (publ) Announces Publication of Abstracts for the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium

author_avatar
NASDAQ Market News

Global Drug Discovery Services Market (2020 to 2025) – Growth in the Biologics Market Presents Opportunities

author_avatar
NASDAQ Market News